The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals Co., Ltd. announced a correction to their previously released FY2024 Third Quarter Consolidated Financial Results Conference Call Material. While the specific corrections are not detailed, such amendments are crucial for maintaining transparency and accuracy in financial communications, which could impact stakeholder trust and the company’s market positioning.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on delivering therapies for rare and genetic diseases. With a 49-year legacy in Japan, it has expanded its presence globally, including in the US, Europe, and Latin America. The company offers approved therapies for various conditions like growth disorder and Fabry disease and is developing treatments for rare diseases such as MPS I, II, and III.
YTD Price Performance: -10.54%
Average Trading Volume: 404,149
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen67.2B
For an in-depth examination of 4552 stock, go to TipRanks’ Stock Analysis page.